Benitec Biopharma Inc. - BNTC
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Dec 08, 2025 | SCHEDULE 13G/A | JANUS HENDERSON GROUP PLC | 9.99% | 3,382,836 | View |
| Dec 08, 2025 | SCHEDULE 13G/A | Janus Henderson Biotech Innovation Master Fund Ltd | 6.1% | 2,067,781 | View |
| Dec 03, 2025 | SCHEDULE 13G | RA Capital Management, L.P. | 5.5% | 1,850,000 | View |
| Dec 03, 2025 | SCHEDULE 13G | Peter Kolchinsky | 5.5% | 1,850,000 | View |
| Dec 03, 2025 | SCHEDULE 13G | Rajeev Shah | 5.5% | 1,850,000 | View |
| Dec 03, 2025 | SCHEDULE 13G | RA Capital Healthcare Fund, L.P. | 5.5% | 1,850,000 | View |
| Nov 10, 2025 | SCHEDULE 13D/A | — | — | — | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.